Bioclinica is a global provider of clinical trial services and technology to contract research organisations (CROs) and pharmaceutical companies.
Bioclinica, headquartered in Pennsylvania, was founded in 1990. It employs more than 2,300 people worldwide and serves more than 400 pharmaceutical, biotechnology and medical device clients across the US, Europe and Asia.
Bioclinica's solutions enhance the overall efficiency and productivity of clinical trials which is a rapidly growing market. The company's core products and services include medical imaging analysis and consultation, cardiovascular safety and efficacy, patient recruitment and retention, central lab services and e-health technologies. The company also benefits from increasing demand for outsourcing and the growing adoption of clinical software services.
Cinven's Healthcare team identified Bioclinica as an investment opportunity based on its significant understanding of the clinical trials industry, and following Cinven's investment in CRO Medpace.
Bioclinica comprises several high growth businesses led by a highly regarded management team. Cinven will support the company's organic growth, as it caters to growing demand across numerous clinical trial service lines and technology areas. Bioclinica will also pursue a selective buy and build strategy. The company has made several add-on investments to-date and is experienced at successfully integrating new businesses.
Cinven will also support the company's expansion into Asia, in particular drawing upon the local knowledge of Cinven's Hong Kong-based Portfolio team.
- 17 July 2017:
Bioclinica Announces AB Cube Has Joined eHealth App xChange
- 16 June 2017:
Bioclinica Launches Clean Patient Optics to Accelerate Database Lock and Clinical Trial Timelines
- 20 October 2016:
Cinven completes acquisition of Bioclinica
- 23 August 2016:
Cinven to acquire Bioclinica